{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Piperacillin&page=3",
    "query": {
      "intervention": "Piperacillin",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Piperacillin&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Piperacillin&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T12:25:28.331Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05753735",
      "title": "eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Fistula"
      ],
      "interventions": [
        {
          "name": "Piperacillin/Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/ Clavulanic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2024-01-18",
      "completion_date": "2024-06-02",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05753735"
    },
    {
      "nct_id": "NCT04983901",
      "title": "PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Imipenem/Cilastatin/Relebactam",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-09-14",
      "completion_date": "2023-10-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04983901"
    },
    {
      "nct_id": "NCT02166476",
      "title": "Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infection Complicated",
        "Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Meropenem-Vaborbactam",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2014-11-20",
      "completion_date": "2016-04-28",
      "has_results": true,
      "last_update_posted_date": "2018-06-11",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 8,
      "location_summary": "Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166476"
    },
    {
      "nct_id": "NCT00491426",
      "title": "Antimicrobial PK in Infants With Suspected or Confirmed Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Infection"
      ],
      "interventions": [
        {
          "name": "Ampicillin",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin/Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Acyclovir",
          "type": "DRUG"
        },
        {
          "name": "Amphotericin B",
          "type": "DRUG"
        },
        {
          "name": "Ambisome",
          "type": "DRUG"
        },
        {
          "name": "Anidulafungin",
          "type": "DRUG"
        },
        {
          "name": "Caspofungin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Days",
        "sex": "ALL",
        "summary": "Up to 120 Days"
      },
      "enrollment_count": 450,
      "start_date": "2006-01",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-19",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00491426"
    },
    {
      "nct_id": "NCT03409679",
      "title": "Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "Murepavadin",
          "type": "DRUG"
        },
        {
          "name": "Two anti-pseudomonal antibiotics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polyphor Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-03-23",
      "completion_date": "2019-07-17",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03409679"
    },
    {
      "nct_id": "NCT02099240",
      "title": "Patients Response to Early Switch To Oral:Osteomyelitis Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Osteomyelitis"
      ],
      "interventions": [
        {
          "name": "oral antibiotics",
          "type": "DRUG"
        },
        {
          "name": "intravenous antibiotics",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Julio Ramirez",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 11,
      "start_date": "2014-03-06",
      "completion_date": "2018-11-07",
      "has_results": false,
      "last_update_posted_date": "2021-04-06",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02099240"
    },
    {
      "nct_id": "NCT06954129",
      "title": "A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 750,
      "start_date": "2026-01-28",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06954129"
    },
    {
      "nct_id": "NCT01923363",
      "title": "PK/PD of High Dose Pip/Tazo in Obese Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Piperacillin/Tazobactam Standard Dose to High Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 29,
      "start_date": "2014-02-25",
      "completion_date": "2016-01-23",
      "has_results": true,
      "last_update_posted_date": "2018-10-26",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01923363"
    },
    {
      "nct_id": "NCT03687255",
      "title": "Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "cefepime/AAI101 combination",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin/tazobactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allecra",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1043,
      "start_date": "2018-09-24",
      "completion_date": "2020-02-15",
      "has_results": false,
      "last_update_posted_date": "2020-03-10",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Buena Park, California • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03687255"
    },
    {
      "nct_id": "NCT03269994",
      "title": "Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Pancreatic Diseases"
      ],
      "interventions": [
        {
          "name": "Cefoxitin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 967,
      "start_date": "2017-11-21",
      "completion_date": "2025-01-28",
      "has_results": true,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-26T12:25:28.331Z",
      "location_count": 29,
      "location_summary": "Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 24 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03269994"
    }
  ]
}